AI Adoption and Data Security in Life Sciences

This report presents findings from a survey conducted by ZoomRx involving over 200 life sciences professionals regarding the adoption of artificial intelligence (AI) in the pharmaceutical industry. The survey reveals that while more than half of life sciences professionals are utilizing ChatGPT in some capacity, a significant number of companies, specifically 65% of the top 20 pharmaceutical firms, have banned its use due to data security concerns. The report outlines that only 60% of companies have provided training or guidelines on using ChatGPT, indicating a gap in employee preparedness. Additionally, the survey highlights that AI is primarily viewed as a tool for cost reduction rather than a driver for business growth. Despite the excitement surrounding AI, many companies are still in the early stages of adoption, with some not having started at all. The report details various motivations for pursuing AI, including cost savings and competitive advantage, while also addressing the concerns surrounding data handling practices.